Every 10-Q that Gain Therapeutics, Inc. (GANX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GANX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GANX filings page.
Gain Therapeutics, Inc. is an early-stage biotechnology company focused on small molecule treatments for protein-misfolding diseases. For the six months ended June 30, 2026, it reported a net loss of $10.3 million, similar to the prior-year period, driven by $4.9 million in research and development expenses and $5.1 million in general and administrative expenses.
Cash and cash equivalents were $13.1 million as of June 30, 2026, down from $20.8 million at year-end 2025, with $9.4 million used in operating activities in the first half of 2026. Management concluded that this cash balance will not fund operations for at least 12 months from issuance of the financial statements and stated that substantial doubt exists about the company’s ability to continue as a going concern beyond the second quarter of 2027 without additional capital.
The company’s lead candidate, rexaceract (GT-02287) for Parkinson’s disease, completed two Phase 1 studies and has an ongoing Phase 1b trial. In June 2026, Gain received FDA Investigational New Drug authorization to begin a Phase 2 study in Parkinson’s disease, anticipated to start in the third quarter of 2026 across sites in the United States, Australia and Europe. To support operations, Gain continues to access its at-the-market equity program and research grants, while also reviewing its cost structure and exploring strategic collaborations.
Gain Therapeutics reported a Q1 2026 net loss of $5.6 million, wider than the $4.5 million loss a year earlier, as research and development and general and administrative expenses both increased.
Cash and cash equivalents were $16.5 million as of March 31, 2026, down from $20.8 million at year-end, with operating activities using $4.7 million of cash in the quarter. The company concluded its current cash will not fund operations for 12 months after these statements are issued, raising substantial doubt about its ability to continue as a going concern absent additional financing.
Gain continues to advance lead candidate GT-02287 for Parkinson’s disease. Two clinical studies are complete, a Phase 1b trial is ongoing, and new 2026 data showed biomarker changes and clinical score improvements in certain participants. The company also raised modest capital via its at-the-market program and warrant exercises and is pursuing further financings, cost optimization, and strategic collaborations.
Gain Therapeutics (GANX) reported Q3 2025 results showing continued investment in R&D and an increased net loss. Net loss was $5.28 million (vs. $4.49 million a year ago), or $(0.15) per share. Operating expenses were $4.79 million. For the first nine months, net loss totaled $15.62 million.
Cash and cash equivalents were $8.81 million at September 30, 2025. The company disclosed that this balance will not fund operations for 12 months from issuance; management stated substantial doubt about continuing as a going concern and plans to seek additional financing and reduce costs to extend runway beyond the first quarter of 2026.
To bolster liquidity year-to-date, GANX raised capital via an ATM program ($4.91 million net) and a July 2025 public offering of 4,501,640 shares and warrants (gross $7.0 million, $6.0 million net), plus an over-allotment of 675,246 shares and additional warrants (gross $1.1 million, $1.0 million net). Cash used in operating activities for the nine months was $13.85 million. Shares outstanding were 35,976,390 as of September 30, 2025; as context, 36,097,536 were outstanding as of October 31, 2025.
Gain Therapeutics reported operating losses and tightened liquidity in the first half of 2025 while continuing clinical development of its lead program. For the six months ended June 30, 2025 the company recorded a $10.34 million net loss, with total operating expenses of $9.46 million. Cash and cash equivalents were $6.69 million at June 30, 2025, down from $10.39 million at year-end 2024, and total assets were $9.83 million versus total liabilities of $6.14 million, leaving stockholders' equity of $3.70 million.
The company disclosed a going concern assessment, stating its June 30, 2025 cash is insufficient to fund operations for 12 months and that it will need additional capital to continue beyond Q1 2026. Management noted recent financings including ATM sales and a July 2025 public offering that generated net proceeds (July offering net proceeds of $6.1 million plus an additional $1.0 million from over-allotment) and described actions to optimize costs and pursue collaborations. The lead clinical candidate GT-02287 completed a Phase 1 study (n=72) that was reported as safe and generally well tolerated, supporting further development.